
Neuroscience company Cerevance announced the completion of its phase 2 clinical trial of CVN424, a once-daily oral compound developed for the treatment of Parkinson’s disease.
According to a company press release, the drug was assessed in a randomized, double-blind, placebo-controlled multicenter study, during which it achieved a significant dose-dependent reduction of “off time,” or periods during the day when Parkinson’s symptoms recur despite medication.
“We are delighted to report these results which we believe demonstrate that CVN424 can provide a significant